Crescent Biopharma, Inc.CBIONASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +0.21% | +0.14% | +0.10% | -40.19% | +156.51% |
| Weighted Average Shares Diluted Growth | +0.21% | +0.14% | +0.10% | -40.19% | +156.51% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | -190.32% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | -193.30% |
| Receivables Growth | -73.40% | -22.32% | -100.00% | -100.00% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -70.49% | -75.52% | -82.48% | +544.72% | +780.80% |
| Book Value per Share Growth | -75.61% | -86.19% | -88.34% | +1060.47% | +299.71% |
| Debt Growth | -74.09% | -91.73% | -100.00% | +266.33% | +564.17% |
| R&D Expense Growth | -67.58% | -95.59% | -99.75% | +92.20% | +1086.17% |
| SG&A Expenses Growth | -11.41% | +17.83% | -53.16% | +119.77% | +38.24% |